Kieu Hoang, Vietnamese-American entrepreneur and former refugee, built a major fortune in medical diagnostics before becoming a high-profile philanthropist and luxury lifestyle investor. After immigrating to the United States with very little, he joined Abbott Laboratories and later founded RAAS, a blood plasma and biotech company that expanded internationally and generated substantial wealth. Hoang went on to acquire and develop vineyards and wineries in Napa Valley and Malibu, combining business with culture, hospitality, and community engagement. Known for his generosity and global perspective, he has donated to health, disaster relief, and cultural causes across Vietnam and the United States.

John W. Brown, former president, CEO, and chairman of Stryker Corporation, is widely regarded as one of the most effective long-tenured CEOs in modern medtech. Taking the helm of the family-run company in 1977, when sales were around $17–23 million, he led Stryker through a landmark IPO, a series of strategic acquisitions, and relentless product expansion, growing revenues into the multi-billion-dollar range and turning it into a global medical technology powerhouse. Under Brown’s three decades of leadership, Stryker evolved from a niche hospital-bed manufacturer into a diversified leader in orthopedics, surgical equipment, and neurotechnology, setting a benchmark for disciplined, long-horizon value creation.  

Joe Kiani, founder, chairman, and CEO of Masimo, is a pioneering medical-technology entrepreneur whose innovations in noninvasive monitoring have transformed modern patient care. Since launching Masimo in 1989, he has built the company into a global leader in pulse oximetry and hospital automation, driven by breakthrough signal-processing technology that set new clinical standards worldwide. Kiani has also become a prominent advocate for patient safety and healthcare transparency, founding the Patient Safety Movement Foundation to reduce preventable hospital deaths. With a blend of engineering vision, mission-driven leadership, and bold industry advocacy, he remains one of the most influential figures in medical technology.

Hansjörg Wyss, Swiss billionaire and philanthropist, built his fortune through medical device maker Synthes, which he sold to Johnson & Johnson for nearly $20 billion in 2012. An engineer by training, Wyss expanded Synthes into a global leader in orthopedic implants before turning his focus to large-scale philanthropy. Through the Wyss Foundation, he has committed billions to environmental conservation, scientific research, and public interest journalism, becoming one of the world’s most influential advocates for protecting wild lands and advancing sustainable solutions.

Gary Michelson, orthopedic spinal surgeon turned inventor and philanthropist, amassed his fortune through more than 950 patents for medical devices, instruments, and procedures that revolutionized spinal surgery. After a landmark $1.35 billion settlement with Medtronic in 2005 over patent disputes, he shifted his focus to philanthropy, founding the Michelson Medical Research Foundation, Michelson 20MM Foundation for education, and Michelson Found Animals Foundation for animal welfare. His career blends groundbreaking medical innovation with a deep commitment to scientific research, education, and social impact.

David C. Paul is an American billionaire engineer-turned-entrepreneur who founded Globus Medical in 2003—a leader in spinal-implant and surgical robotics technologies. An immigrant from India with degrees in mechanical engineering from the University of Madras and Temple University, he guided the company to IPO in 2012 and remains its controlling Executive Chairman. Paul holds over 200 patents and built his $1.4 billion fortune through robotics innovation. 

Carl Cook is an American billionaire and chief executive of Cook Group, the prominent medical device company founded by his parents, William and Gayle Cook. A Purdue engineering graduate and University of Iowa MBA, he took over as CEO in 2011 following his father’s passing. Today, he leads the firm’s expansion across diagnostics, life sciences, and cell-therapy research via Cook MyoSite. Known for his low-profile leadership, Cook oversees a multibillion-dollar legacy while quietly advancing medical innovation.